(Q39033763)

English

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

scientific article published on 9 April 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Geneviève Chêne

16

object named as

Geneviève Chêne

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

object named as

Carlos Brites

7

0 references

Beatriz Grinsztejn

1

object named as

Beatriz Grinsztejn

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Constance Delaugerre

15

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jean-Michel Molina

17

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Mariza Gonçalves Morgado

5

object named as

Mariza Morgado

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Nêmora Tregnago Barcellos

9

object named as

Nêmora Tregnago Barcellos

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Nathalie De Castro

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Vincent Arnold

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Valdiléa G Veloso

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

José Henrique Pilotto

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

José Valdez Madruga

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Breno Riegel Santos

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Carla Vorsatz

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Catherine Fagard

12

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Marilia Santini-Oliveira

13

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Olivier Patey

14

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

ANRS 12 180 Reflate TB study group

18

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

9 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

459-467

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Integration of antiretroviral therapy with tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2814%2970711-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(14)70711-X

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39033763&oldid=1986242440"